RestructuringJun 15, 2026, 04:22 PM
Adaptive Biotechnologies Plans Business Separation; Offers $250M Notes
AI Summary
Adaptive Biotechnologies announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses, aiming to unlock potential and create shareholder value. The company will focus on its profitable MRD diagnostics business, while evaluating strategic alternatives for Immune Medicine by year-end 2026. Concurrently, Adaptive intends to offer $250 million in convertible senior notes due 2031, with proceeds primarily used to repay the OrbiMed Purchase Agreement ($156.9 million), fund capped call transactions, and repurchase up to $25 million of common stock.
Key Highlights
- Adaptive Biotechnologies plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.
- The MRD business generated $212 million in revenue and $15 million in adjusted EBITDA in 2025.
- Immune Medicine has over 6 million functional T-cell receptor (TCR)-antigen pairs and data from 10,000+ patients.
- The company intends to offer $250 million in convertible senior notes due 2031.
- Initial purchasers have an option to buy up to an additional $37.5 million in notes.
- Proceeds will repay the OrbiMed Purchase Agreement with a $156.9 million payoff amount.
- Up to $25 million of net proceeds will be used to repurchase common stock.
- Proceeds will also fund capped call transactions to reduce potential dilution.
Price Impact
More from ADPT